natamycine

composé chimique

Resous ekstèn

idantifyan sou Freebase
identifiant Microsoft Academic
identifiant PubChem (CID)
identifiant Medical Subject Headings
D010866

sous le nom: Natamycin

UniChem compound ID
identifiant KEGG
identifiant Encyclopædia Britannica
topic/natamycin

sous le nom: natamycin

identifiant Classification anatomique, thérapeutique et chimique
identifiant WikiProjectMed
PesticideInfo chemical ID
RxNorm CUI
identifiant Open Food Facts d'un additif alimentaire
code UNSPSC
numéro NSC
identifiant OpenAlex
identifiant ChEMBL
numéro CAS
Natural Product Atlas ID
InChIKey
identifiant DrugBank
numéro E
identifiant ChEBI
7488[14][15][16]

lien de concordance: équivalence exacte

InChI
numéro CosIng
identifiant Electronic Essential Medicines List
identifiant Brockhaus Enzyklopädie
identifiant SureChEMBL
identifiant Human Metabolome Database
arborescence MeSH
UMLS CUI
SPLASH
identifiant Open Food Facts d'un ingrédient
identifiant Store medisinske leksikon
natamycin[19]

sous le nom: natamycin

lien de concordance: équivalence exacte

identifiant DSSTOX d'un composé chimique
identifiant DSSTOX
identifiant d'InfoCard ECHA
identifiant ChemSpider
numéro CE
DrugCentral ID
identifiant National Drug File
identifiant NALT
identifiant Encyclopédie de Chine (troisième édition)
identifiant Probes And Drugs
identifiant Unique Ingredient Identifier

se yon

type d'entité chimique

sou-klas

polyene macrolide

itilizasyon

additif alimentaire
médicament[23]

structure chimique

masse

665,305 unité de masse atomique unifiée[2]

stéréoisomère de

(1R,3S,5R,7R,12R,22R,24S,25R,26S)-22-[(2R,3S,4S,5S,6R)-4-amino-3,5-dihydroxy-6-methyloxan-2-yl]oxy-1,3,26-trihydroxy-12-methyl-10-oxo-6,11,28-trioxatricyclo[22.3.1.05,7]octacosa-8,14,16,18,20-pentaene-25-carboxylic acid[12][24]

formule chimique

C₃₃H₄₇NO₁₃[2]

SMILES canonique

CC1CC=CC=CC=CC=CC(CC2C(C(CC(O2)(CC(CC3C(O3)C=CC(=O)O1)O)O)O)C(=O)O)OC4C(C(C(C(O4)C)O)N)O[2]

SMILES isomérique

C[C@@H]1C/C=C/C=C/C=C/C=C/[C@@H](C[C@H]2[C@@H]([C@H](C[C@](O2)(C[C@H](C[C@@H]3[C@H](O3)/C=C/C(=O)O1)O)O)O)C(=O)O)O[C@H]4[C@H]([C@H]([C@@H]([C@H](O4)C)O)N)O[2]

dose thérapeutique quotidienne

25 milligramme[25]

voie d'administration: voie vaginale

0,3 gramme[26]

voie d'administration: voie orale

20 milligramme[27]

voie d'administration: voie orale

est le principe actif dans

Natacyn[28]

dénomination commune internationale des substances pharmaceutiques

natamycin[6]

maladie traitée

conjonctivite[54]
coccidioïdomycose[54]
aspergillose[54]
mycose[54]
blépharite[54]
microsporidiose[54]
blastomycose[54]
candidose[54]
cryptococcose[54]
sporotrichose[54]
histoplasmose[54]
kératite[54]
kératite[55]

approuvé par: Food and Drug Administration

dat kòmansman: 13 jen 1980

conjonctivite[55]

approuvé par: Food and Drug Administration

dat kòmansman: 13 jen 1980

blépharite[55]

approuvé par: Food and Drug Administration

dat kòmansman: 13 jen 1980

rôle du sujet

antiseptique local[56]
antimycosique[56]

catégorie Commons

Natamycin

Referans

  1. sauvegarde de la base de données Freebase, 28 oktòb 2013
  2. 2,0 2,1 2,2 2,3 2,4 2,5 et 2,6 PubChem, 17 novanm 2016, angle, 5284447, pimaricin
  3. 3,0 3,1 3,2 3,3 3,4 et 3,5 NCXMLFZGDNKEPB-FFPOYIOWSA-N, InChIKey
  4. 4,0 4,1 4,2 et 4,3 NCXMLFZGDNKEPB-BQGNJOPGSA-N, InChIKey
  5. 5,0 et 5,1 UniChem
  6. 6,0 et 6,1 ChEMBL, 19 janvye 2016, angle, Natamycin, CHEMBL1200656
  7. 7,0 7,1 7,2 7,3 et 7,4 DrugBank, angle, 17 novanm 2015, 00826, Natamycin
  8. 8,0 8,1 8,2 8,3 8,4 et 8,5 Global Substance Registration System, 17 novanm 2016, angle, natamycin, 8O0C852CPO
  9. OpenAlex, 26 janvye 2022, https://docs.openalex.org/download-snapshot/snapshot-data-format
  10. ChEMBL, 17 novanm 2016, angle, NATAMYCIN, CHEMBL1200656
  11. CAS Common Chemistry, 10 avril 2021, https://commonchemistry.cas.org/detail?cas_rn=7681-93-8, NCXMLFZGDNKEPB-FFPOYIOWSA-N
  12. 12,0 12,1 12,2 12,3 et 12,4 inferred from InChIKey
  13. ChEBI release 2020-09-01
  14. ChEBI release 2019-10-02
  15. ChEBI release 2021-03-01
  16. InChI=1S/C33H47NO13/c1-18-10-8-6-4-3-5-7-9-11-21(45-32-30(39)28(34)29(38)19(2)44-32)15-25-27(31(40)41)22(36)17-33(42,47-25)16-20(35)14-24-23(46-24)12-13-26(37)43-18/h3-9,11-13,18-25,27-30,32,35-36,38-39,42H,10,14-17,34H2,1-2H3,(H,40,41)/b4-3+,7-5+,8-6+,11-9+,13-12+/t18-,19-,20+,21+,22+,23-,24-,25+,27-,28+,29-,30+,32+,33-/m1/s1, International Chemical Identifier
  17. base de données CosIng, 28 desanm 2019, 91607, NATAMYCIN, CAS no.: 7681-93-8
  18. https://list.essentialmeds.org/medicines/230, eEML - Electronic Essential Medicines List, 23 oktòb 2021
  19. Store norske leksikon, 5 jen 2020
  20. Mapping file of InChIStrings, InChIKeys and DTXSIDs for the EPA CompTox Dashboard
  21. base de données InfoCard de l'ECHA, 27 desanm 2018, 100.028.803, Natamycin, CAS no.: 7681-93-8
  22. ChemSpider, 17 novanm 2016, angle, 10468784, Natamycin
  23. DrugBank, angle, 17 novanm 2015, Natamycin, 00826
  24. inferred from InChI
  25. https://www.whocc.no/atc_ddd_index/?code=G01AA02
  26. https://www.whocc.no/atc_ddd_index/?code=A07AA03
  27. https://www.whocc.no/atc_ddd_index/?code=A01AB10
  28. RxNorm, 202743, 14 fevriye 2018
  29. The structure of the macrolide antibiotic pimaricin
  30. 30,0 30,1 30,2 et 30,3 Enhancement of natamycin production on Streptomyces gilvosporeus by chromosomal integration of the Vitreoscilla hemoglobin gene (vgb).
  31. 31,0 31,1 31,2 et 31,3 Bidirectional Regulation of AdpAch in Controlling the Expression of scnRI and scnRII in the Natamycin Biosynthesis of Streptomyces chattanoogensis L10.
  32. 32,0 32,1 32,2 et 32,3 Improvement of Natamycin Production by Cholesterol Oxidase Overexpression in Streptomyces gilvosporeus
  33. 33,0 33,1 33,2 et 33,3 Multiple transporters are involved in natamycin efflux in Streptomyces chattanoogensis L10.
  34. 34,0 34,1 34,2 et 34,3 Improvement of natamycin production by engineering of phosphopantetheinyl transferases in Streptomyces chattanoogensis L10.
  35. 35,0 35,1 35,2 et 35,3 Enhanced Natamycin production by Streptomyces natalensis in shake-flasks and stirred tank bioreactor under batch and fed-batch conditions
  36. 36,0 36,1 36,2 et 36,3 Physicochemical and microbial responses of Streptomyces natalensis HW-2 to fungal elicitor
  37. 37,0 37,1 37,2 et 37,3 Production of natamycin by Streptomyces gilvosporeus Z28 through solid-state fermentation using agro-industrial residues
  38. 38,0 38,1 38,2 et 38,3 Rational construction of genome-reduced and high-efficient industrial Streptomyces chassis based on multiple comparative genomic approaches
  39. 39,0 39,1 39,2 et 39,3 Complete Genome Sequence of the High-Natamycin-Producing Strain Streptomyces gilvosporeus F607.
  40. 40,0 40,1 40,2 et 40,3 WblAch, a pivotal activator of natamycin biosynthesis and morphological differentiation in Streptomyces chattanoogensis L10, is positively regulated by AdpAch
  41. 41,0 41,1 41,2 et 41,3 Effects of cultivation conditions on the production of natamycin with Streptomyces gilvosporeus LK-196.
  42. 42,0 42,1 42,2 et 42,3 Genome mining and homologous comparison strategy for digging exporters contributing self-resistance in natamycin-producing Streptomyces strains
  43. 43,0 43,1 43,2 et 43,3 Solubility properties and diffusional extraction behavior of natamycin from Streptomyces gilvosporeus biomass
  44. 44,0 44,1 44,2 et 44,3 Genome-wide analysis of the regulation of pimaricin production in Streptomyces natalensis by reactive oxygen species.
  45. 45,0 45,1 45,2 et 45,3 Construction of a Streptomyces lydicus A01 transformant with a chit42 gene from Trichoderma harzianum P1 and evaluation of its biocontrol activity against Botrytis cinerea.
  46. 46,0 46,1 46,2 et 46,3 Influence of fungal elicitors on biosynthesis of natamycin by Streptomyces natalensis HW-2
  47. 47,0 47,1 47,2 et 47,3 SlnM gene overexpression with different promoters on natamycin production in Streptomyces lydicus A02.
  48. 48,0 48,1 48,2 et 48,3 Characterization of type II thioesterases involved in natamycin biosynthesis in Streptomyces chattanoogensis L10.
  49. 49,0 49,1 49,2 et 49,3 Biosynthesis regulation of natamycin production from Streptomyces natalensis HDMNTE-01 enhanced by response surface methodology.
  50. 50,0 50,1 50,2 et 50,3 Identification of a secondary metabolism-responsive promoter by proteomics for over-production of natamycin in Streptomyces
  51. A complex multienzyme system encoded by five polyketide synthase genes is involved in the biosynthesis of the 26-membered polyene macrolide pimaricin in Streptomyces natalensis
  52. Iteratively improving natamycin production in Streptomyces gilvosporeus by a large operon-reporter based strategy
  53. AB-400, a new tetraene macrolide isolated from Streptomyces costae
  54. 54,00 54,01 54,02 54,03 54,04 54,05 54,06 54,07 54,08 54,09 54,10 et 54,11 N0000146913, 13 desanm 2016, angle, NDF-RT
  55. 55,0 55,1 et 55,2 Inxight: Drugs Database, 2 novanm 2018, https://drugs.ncats.io/drug/8O0C852CPO, http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050514s009lbl.pdf
  56. 56,0 56,1 et 56,2 Medical Subject Headings, 15 mas 2018, D010866